Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

company.png

March 2, 2017 OrthoSpineNews

 Ecully, 1 March 2017

Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine,) announces the signature of a contract with a new US distributor for the sale of its implants and instruments.

The distributor is based in the Midwest and has a client portfolio that includes several hospitals and surgical centers. Spineway USA Inc. received a 1st order for a hospital in the region and should receive a 2nd order in April. These orders are for items from the Mont Blanc and the Twin Peaks lines, which are the Spineway Group’s mid-range offerings.

This new distribution contract is in addition to the two already signed, one with a California distributor (September 2016) and the other with a Texas distributor (January 2017), thus allowing Spineway to create a network that is slowly expanding throughout the United States.

Philippe Laurito becomes President of Spineway USA Inc.

In order to steer and roll out Spineway’s offer in the US, Philippe Laurito, Managing Director of Spineway, will become President of the Group’s US subsidiary as from 1 March 2017.

His expertise and in-depth knowledge of the American continent will allow him to guide and expedite the sale of Spineway products on the largest market in the world for spinal surgery. Philippe Laurito remains Deputy Managing Directory and member of the Spineway Group’s Executive Committee.

Thanks to these three distribution contracts and the in-situ steering of its US subsidiary, Spineway should increase its presence on the territory and see its sales grow quickly to represent at a short term almost 40% of the total sales of the group.

SPINEWAY IS ELIGIBLE FOR THE PEA-PME (EQUITY SAVINGS PLAN FOR SMES)
Find out all about Spineway at www.spineway.com

Next communication:
2016 Annual Results – 25 April 2017, after market closes

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) – Talent INPI award (2015).
ISIN code: FR0011398874 – ALSPW     

Contacts:

Investor Relations
David Siegrist – Finance Director
Tel: +33 (0)4 72 77 01 52
finance.dsg@spineway.com
Financial Communication
Jérôme Gacoin / Solène Kennis
Tel: +33 (0)1 75 77 54 68
skennis@aelium.fr

Screen-Shot-2015-09-28-at-1.57.38-PM.png

March 2, 2017 OrthoSpineNews

CARLSBAD, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) — Alphatec Spine, Inc., (Nasdaq:ATEC), a global provider of spinal fusion technologies, announced today that the Company has launched its new Arsenal Deformity Adolescent Idiopathic Scoliosis (AIS) System and has successfully completed initial patient cases.  The limited release further expands the Company’s Arsenal Spinal Fixation System and targets the $650M U.S. deformity spine market.

The Arsenal AIS System gives surgeons a complete solution to address complex deformity pathologies, including unique uniplanar screws, which enable easier screw positioning and rod placement through a tulip that has 360 degrees of rotation, while restricting motion in the medial/lateral plane for derotation correction.  Additionally, the AIS system includes a wide variety of low-profile implants providing a better anatomical fit and increased ability to address patient pathologies, ergonomically designed instrumentation to improve surgical efficiency and comfort during complex surgeries, and proven biomechanical strength necessary to achieve a solid fusion.

Terry Rich, Alphatec Spine’s Chief Executive Officer commented, “With the launch of our differentiated AIS Deformity System we are able to compete directly with the market leaders in complex spine and it opens up a new segment for us in pediatric procedures.  This unique system extends our Arsenal platform and provides surgeons with easy-to-use, differentiated surgical tools for corrective maneuvers to better treat adolescent patients who are diagnosed with idiopathic scoliosis.  These successful initial patient cases demonstrate ATEC’s ongoing commitment to developing innovative solutions that are targeted at improving overall patient outcomes and surgeon experience.  The Arsenal AIS system gives us the opportunity to gain greater share in the deformity market and to benefit a vast number patients who are suffering today.”

Dr. Sheldon St. Clair, a pediatric orthopedic surgeon, and Dr. John Birknes, a pediatric neurosurgeon,  co-directors of the Spine Program at the Children’s Hospital of the King’s Daughters in Virginia, have partnered to treat pediatric spine deformities and performed the first deformity correction using the Arsenal AIS system. The patient was a skeletally immature 13-year-old with a hypokyphotic 49-degree thoracic scoliosis.  Drs. St. Clair and Birknes performed the surgery using the Arsenal uniplanar implants and cobalt-chromium alloy rods on a long construct across 9 levels from thoracic vertebrae T3 to T12.  Post-surgery, the patient’s thoracic curve has been eliminated, appropriate kyphosis has been restored, and the patient’s rib hump is no longer present.

“The entire Arsenal Deformity AIS set is fantastic, but the shining star is the ability to spin the uniplanar bodies independent of the screw shank, which allows surgeons to achieve optimal fixation and placement of the pedicle screws,” said Dr. St. Clair. “This unique feature enables the tulips to be placed at the perfect height and orientation to accept the rod and correct the deformity.  The slotted reduction towers are used both to reduce the rod into the tulips as well as to perform vertebral column manipulation to correct the spine in three planes of deformity. The reduction towers and transverse links are designed to be attached and removed with ease. The Arsenal AIS system provides strong, reliable implants, and two choices of cobalt chrome rods, enabling the surgeon to obtain excellent spinal deformity correction, which improves quality of life for the patient both now and for the future.”

About Alphatec Spine

Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC), is a medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company’s mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. via a direct sales force and independent distributors.

Additional information can be found at www.alphatecspine.com.

Forward Looking Statements  

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management’s current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors.  Forward-looking statements include the Company’s ability to achieve profitable growth; the Company’s ability to achieve both domestic and international growth and future profitability.  The words “believe,” “will,” “should,” “expect,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement.  The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine’s pipeline within forecast timeframes, or at all, including without limitation the products discussed in this press release; the Company’s ability to compete directly with the market leaders in complex spine and open up a new segment for the Company in pediatric procedures; the Company’s ability to gain greater share in the deformity market and to benefit a vast number patients in such market; the acceptance of Alphatec Spine’s products by the surgeon community, including without limitation the products discussed in this press release;  and Alphatec Spine’s ability to develop and expand its U.S. revenues.  Please refer to the risks detailed from time to time in Alphatec Spine’s SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K.  Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

CONTACT: Investor/Media Contact:

Christine Zedelmayer
Investor Relations 
Alphatec Spine, Inc.
(760) 494-6610
czedelmayer@alphatecspine.com

Mazor-X.jpg

March 1, 2017 OrthoSpineNews

ORLANDO, FL–(Marketwired – March 01, 2017) – Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR), a pioneer and leader in the field of surgical guidance systems, will demo the new Mazor X system at Spine Summit 2017, the Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves in Las Vegas, March 8-11.

Visit booth #1110 during exhibit hours or attend the following special presentations to learn more about Mazor X:

Lunch Seminar: Introducing Mazor X™: Mazor Robotics’ Next-Gen System
Moderator: Dr. Michael Steinmetz
Location: Valencia Ballroom
Date: Wednesday, March 8
Time: 12:30 – 1:30 pm

“What’s New” Session: Clinical Experience of Mazor Robotics Guidance Systems and O-Arm® Imaging in Degenerative and Deformity Cases
Faculty: Dr. Jeffrey L. Gum
Location: Demo Theater
Date: Friday, March 10
Time: 9:47 – 9:57 am

The Mazor X system consists of sophisticated 3D planning tools and an intra-op guidance system with a precision Surgical Arm indicated for implant and instrument positioning in spine surgery — the core of the Surgical Assurance Platform.

“Mazor’s core technology has been used in over 23,000 procedures. This unparalleled clinical and operating room experience has provided us with deep insight into what the surgeons want next for themselves and their patients,” said Mazor Robotics CEO Ori Hadomi. “So, we pushed the envelope, moving from a precise mechanical system, to a complete expandable platform that incorporates integrated analytics and state-of-the art guidance.”

“You plan your surgery and there is no heartache anymore,” said Orthopedic Surgeon Kornelis Poelstra, MD, PhD. “You know exactly where the screws are going to go.” Click here to watch full testimonial

Following Spine Summit, Mazor Robotics will also be exhibiting Mazor X at AAOS Annual Meeting in San Diego, March 14-18 (booth #2339).

About Mazor

Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit MazorRobotics.com.

Image Available: http://www.marketwire.com/library/MwGo/2017/2/28/11G131731/Images/mazor_bot-81c042b0c45195a0b5cfdad64568b31a.jpg

CONTACT INFORMATION


illus_11_.0-copie-750x0-c-default.jpg

March 1, 2017 OrthoSpineNews

March 1, 2017

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–

IMPLANET (IMPL.PA) (IMPZY) (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, announces that the French patent office has granted a patent protecting the JAZZ Lock® implant in France.

A major component of an innovative range of band products for spine surgery, Jazz Lock® is an implant designed to treat degenerative spine disorders, whose global market potential is estimated at over $200 million.

An unrivaled implant, thanks to its locking system requiring no rod fixation, Jazz Lock® allows surgeons to shorten and simplify the surgical procedure by removing multiple steps and implants used in traditional system: locking screws and connecting rods.

Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “Obtaining this patent from the French patent office is the first step in fully protecting our Jazz Lock®, and more particularly, its locking mechanism that is the first of its kind in the market. The protection of this latter element is pivotal, insofar as the majority of our future developments will incorporate this technology. We continue to be extremely rigorous regarding the protection of our current and future innovations.”

Ludovic Lastennet, CEO of Implanet, adds: “We are continuing the strict execution of our development strategy, of which the comprehensive protection of our products is a major component. We have submitted the dossier to various global intellectual property authorities, notably the United States. Since its limited launch last autumn in the United States and Europe, Implanet has sold more than 300 Jazz Lock® implants to treat degenerative spine disorders. The clinical feedback from surgeons has been excellent, including important practical aspects such as ease of use and speed of implementation.

Next financial press release: 2016 annual results, on March 28, 2017

IMPLANET will participate in the following events:

  • GES (“Groupement d’étude sur la Scoliose” scoliosis study group), Strasbourg, France, March 9 to 11, 2017
  • AAOS (American Academy of Orthopedic Surgery), San Diego CA, USA, March 15 to 17, 2017

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2016 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228007033/en/


invivo-therapeutics-7x4.jpg

February 28, 2017 OrthoSpineNews

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that two INSPIRE study Principal Investigators, Dom Coric, M.D. and Michael Fehlings, M.D., Ph.D., will be giving oral presentations at the Spine Summit 2017 to be held March 8-11, 2017 in Las Vegas, NV. Dr. Coric will present “INSPIRE Study Update on 10 Subjects Implanted with a Bioresorbable Polymer Scaffold Following Acute Complete Thoracic Spinal Cord Injury,” and Dr. Fehlings will present “Magnetic Resonance Imaging (MRI) Does Not Distinguish between Contusion and Compound Cord Lesions Following Severe (AIS A) Traumatic Acute Thoracic Cord Injury: Intraoperative Microsurgical Observations from the INSPIRE Trial” during the Peripheral Nerve, Basic Science Breakout session on Saturday, March 11.

Dr. Fehlings will also present during a What’s New Session on Friday, March 10. The session will include discussion of the Neuro-Spinal Scaffold™technology and INSPIRE study and will continue to raise awareness amongst leading spine neurosurgeons.

Mark Perrin, Chairman and CEO, said, “The Spine Summit affords us the opportunity to build mindshare within the most pertinent group of surgeons for the Neuro-Spinal Scaffold. This meeting has proven to be one of the most fruitful in terms of bringing on board new INSPIRE sites, and we look forward to having a significant presence at this meeting.”

The company will also have an exhibit booth to further foster relationships with the neurosurgical community. The meeting is the 33rd Annual Meeting of the AANS/CNS (American Associations of Neurological Surgeons / Congress of Neurological Surgeons) Joint Section on Disorders of the Spine and Peripheral Nerves and is being held in collaboration with the Korean Spinal Neurosurgery Society.

About the Neuro-Spinal Scaffold™ Implant

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and is designed to act as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the addition of new sites. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the ability to complete the INSPIRE study and submit an HDE; the company’s ability to receive regulatory approval for the Neuro-Spinal Scaffold; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2015, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics
Brian Luque, 617-863-5535
Investor Relations
bluque@invivotherapeutics.com


IMG_6512-1830399774.jpg

February 28, 2017 OrthoSpineNews

February 27, 2017

IRVINE, Calif.–(BUSINESS WIRE)–joimax® further ensures its market access in Asia. The German based market leader of technologies and training methods for endoscopic minimally invasive spinal surgery is expanding its presence and recently has obtained full product registration from the Thai Food & Drug Administration (FDA). joimax® also has approvals in South Korea, China, Singapore, Indonesia, Hong Kong and Vietnam. For Malaysia, Taiwan and Japan, the certification for the product range is expected in 2017. “We are constantly pushing the registration process in Asia to extend the availability of joimax® products. Thus, joimax® is well prepared to further widen its market presence in Asia, demonstrating our commitment to the fastest growing region of the world,” states Wolfgang Ries, Founder and CEO of joimax®.

For years, joimax® has been working with the Korean Wooridul group, the world’s largest Specialized Spine Hospital Network. Starting in 2017, joimax®, together with the Wooridul Hospital in Seoul, will offer International courses for Minimally Invasive Spinal Surgery (MISS). In a series of four courses, provided in basic and advanced level, the education of international spine surgeons is ensured. The first one, chaired by joimax® faculty Dr. Sang-Ho Lee, South Korea, recently took place. The one-week training programs offer surgeons the opportunity to learn percutaneous endoscopic techniques and other minimally-invasive procedures with lectures, operation observation and hands-on-workshops. Since 2004, more than 600 spine surgeons and specialists from 41 countries have participated in these courses at Wooridul.

After the National Minimal Invasive Spinal Summit Forum, together with the 4th joimax® User Meeting in December, joimax® China, headquartered in Chengdu, will celebrate its 10th birthday in April 2017. On this occasion, numerous internationally well-known faculties will meet in Chongqing, China to share experience and expertise. Lectures and live surgeries are planned to be held in two hospitals and to be broadcasted via Internet.

About joimax®

Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® RT (e.g. for rhizotomy) and with MultiZYTE® SI for SI-Joint therapy or with EndoLIF® and Percusys® for endoscopic minimally-invasive assisted stabilizations, proven endoscopic systems are provided that, together, cover a whole variety of indications.

In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions – under local or full anesthetic – via tissue and muscle-sparing corridors through natural openings into the spinal canal (e.g. intervertebral foramen, the “Kambin triangle”).

Contacts

Press Contact USA:
joimax® Inc.
Melissa Brumley, 001 949 859 3472
Melissa.brumley@joimaxusa.com


article-Philips-Surgical-Navigation-Technology-based-on-Augmented-Reality-3.jpg

February 27, 2017 OrthoSpineNews

24th February 2017

Philips’ new augmented reality system has been used in clinical practice for the first time at the Karolinska University Hospital, Solna, Sweden.

“This new technology allows us to use augmented reality in combination with 3D imaging for intraoperative surgical planning and navigation of our devices. We have now treated four patients using the system and placed 44 pedicle screws with satisfactory results. We have been able to check the overall result in 3D in the operating room without the need to move the patient to a CT scanner. The radiation dose to the staff is zero and minimal to the patient.” said Adrian Elmi-Terander, principal investigator at Karolinska University Hospital, Solna, Sweden. “We tested this workflow pre-clinically for complex thoracic and cervical spine surgeries with very convincing results and look forward to extending it to complex cerebral neurosurgical procedures.”

A pre-clinical study published in Spine has demonstrated superior accuracy for thoracic pedicle screws placement using an augmented-reality navigation system (Philips) in comparison to those placed freehand.

The system consists of four high resolution optical video cameras mounted to in the frame of a motorised ceiling-mounted C-arm flat detector (Allura Clarity FD20, Philips Healthcare). Between eight and 10 markers were placed on the skin around the surgical site on each of four human cadavers for tracking by the system.

 

READ THE REST HERE


hqdefault-1.jpg

February 23, 2017 OrthoSpineNews

Pain management doctor, Andrew Cottingham, MD of OPTIMAL Pain & Regenerative Medicine is the first physician in North Texas to implant the new Vertiflex Superion Indirect Decompression System®. The Vertiflex Superion is a minimally invasive, safe, out-patient procedure that gives patients an alternative to spine surgery for the treatment of lumbar spinal stenosis.

Back and leg pain affects millions of Americans every year. Lumbar spinal stenosis is caused by aging and “wear” on the discs between the vertebrae. The degeneration of the discs causes the spinal canal to narrow, which leads to additional pressure on the nerves in the lower back. This pressure leads to lower back pain and radiating leg, buttock and/or groin pain. Symptoms typically intensify during standing and walking and decrease when sitting and bending forward.

Conservative treatment of lumbar spinal stenosis typically involves rest, physical therapy, medication management and epidural steroid injections. When non-surgical treatment does not alleviate symptoms, surgical treatment historically involves direct compression surgery. The Vertiflex Superion device is an FDA approved minimally invasive treatment option for patients suffering from lower back pain and radiating leg pain caused by lumbar spinal stenosis.

The procedure uses a Superion implant, which is a small titanium device that is inserted through a small incision in the lower back. The implant is then placed in the spinal structure to keep the spine positioned such that the nerves in the spinal canal are not compressed. The device has been implanted in more than 2,000 patients worldwide. The clinical trial results showed a decrease in pain. Four years post-procedure, almost 90% of the clinical trial patients expressed continuing satisfactory results.

“The Vertiflex Superion is an elegant, minimally invasive procedure that can change so many people’s lives who are suffering from lower back pain and radiating leg pain caused by lumbar spinal stenosis,” said Dr. Andrew Cottingham.

To learn if you are a candidate, please call us at 817-468-4343 or visit our website: The Vertiflex Superion Procedure.

About OPTIMAL Pain & Regenerative Medicine

The pain management doctors at OPTIMAL, Drs. Cottingham, Berlin and Phillips, are dedicated to staying on the forefront of pain management and regenerative medicine procedures. Each physician is double-board certified in anesthesiology and pain medicine. Through their collective expertise, the OPTIMAL team delivers comprehensive, current and compassionate medical care to patients in Dallas, Fort Worth and Arlington, Texas.


board_of_directors.jpg

February 23, 2017 OrthoSpineNews

Minimus Spine, manufacturer of the Triojection® system for herniated spinal discs, is announcing the appointment of Jeffrey R. Binder to its Board of Directors. Mr. Binder was the CEO of Biomet from 2007 until it was acquired for approximately $14 billion by Zimmer Holdings in 2015. Mr. Binder is currently the President and CEO of Immucor. Prior to his time at Biomet, Mr. Binder was president of Abbott Diagnostics from 2006 to 2007 and the CEO of Spinal Concepts from 2000 until it was acquired by Abbott Laboratories in 2003 and became Abbott Spine. Prior to Spinal Concepts, Mr. Binder was President of Depuy Orthopedics and he has spent most of his career in orthopedics and spine.

David Hooper, PhD, Minimus Spine’s President and CEO said, “Jeff brings a wealth of intellect and experience to Minimus. He has successfully orchestrated several significant transactions in spine and orthopedics and is unquestionably a blue-chip addition as we strengthen the team around Triojection. Our management team and board worked together at Spinal Concepts. While that was a great result, the market need has expanded far beyond spinal hardware. We share the vision that Minimus is part of the future of spine and we expect continued success as we plan the initial commercial launch of Triojection in Europe this summer.”

Mr. Binder added: “I am very pleased to join the board of this exciting and innovative young company. Clinicians and patients are searching for solutions that address spinal disorders and reduce pain with less invasive approaches. I’m looking forward to working again with David and fellow director Wes Johnson, who were both so instrumental to our success at Spinal Concepts.”

Minimus Spine is dedicated to the non-surgical treatment of disc herniation patients using an intradiscal injection of ozone gas to the herniated disc. Minimus Spine is the manufacturer of the Triojection System, which involves a sterile, single-use, syringe cartridge that is processed in the operating room using the Triojection console. Triojection provides the physician with confidence in both the sterility of the procedure and the concentration of ozone delivered to the patient.


varilift_lx_922_312_c1.png

February 22, 2017 OrthoSpineNews

February 22, 2017

AUSTIN, Texas–(BUSINESS WIRE)–

Wenzel Spine, Inc., a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders, today announced that it has completed the acquisition of the PrimaLOK™ SP Interspinous Fusion System and PrimaLOK™ FF Facet Fixation System from OsteoMed, LLC.

The PrimaLOK SP & FF platforms include a polyaxial interspinous process device and percutaneous facet screw system designed for MIS applications in treatment of lumbar spinal disorders. These patented technologies are designed to provide surgeons an expanded MIS solution when used in conjunction with the stand-alone, expandable, VariLift-LX interbody fusion device.

“This acquisition provides our distributors and surgeons a powerful combination of MIS solutions. When paired with our VariLift-LX stand-alone, expandable, interbody technology, surgeons now have the ability to provide supplemental fixation, when needed, without having to revert to pedicle screw constructs,” said Chad Neely, President and Chief Executive Officer of Wenzel Spine. “In addition, this expands our current product portfolio while strengthening our development pipeline and demonstrating our commitment to the development of innovative MIS solutions to our distribution and surgeon partners.”

Dr. Charles Gordon, the inventor of the PrimaLOK SP System, and founder of the Texas Spine & Joint Hospital, commented, “I am pleased that Wenzel Spine has added the PrimaLOK Systems to their product portfolio. We are very happy to be partnered with a Spine focused company and believe Wenzel Spine is the ideal partner to bring the full potential of the PrimaLOK Systems to market.” Dr. Gordon further commented, “There are tremendous MIS innovation opportunities in combining the advantages of the PrimaLOK and VariLift-LX technologies.”

Wenzel Spine plans to integrate the PrimaLOK platforms into the pipeline of innovative MIS solutions currently being developed. The company has completed a limited US release of the PrimaLOK SP & FF Systems and expects to offer wide US release of the products in the second quarter of 2017.

About Wenzel Spine, Inc.

Wenzel Spine, Inc. is a medical technology company focused on providing minimally invasive solutions for the treatment of spinal disorders. Headquartered in Austin, TX, Wenzel Spine is focused on delivering surgical solutions that improve the overall quality of spine care by simplifying procedures and reducing recovery time. Wenzel Spine seeks to improve patient quality of life by designing and producing devices of the highest quality to support our surgeon clients in the care and treatment of their patients. For more information about the company and our products, visit www.wenzelspine.com

Follow Wenzel Spine on LinkedIn: https://www.linkedin.com/company/wenzel-spine
Follow Wenzel Spine on Twitter: https://twitter.com/WenzelSpine
Follow Wenzel Spine on Facebook: https://facebook.com/WenzelSpine
Follow Wenzel Spine on Instagram: https://Instagram.com/wenzelspine

View source version on businesswire.com: http://www.businesswire.com/news/home/20170222005421/en/